Technical / White Paper
Simpler and Faster Viral Vector Production Scale-Up

Discover how to efficiently produce wild-type or recombinant viruses to be used as vaccines and human gene therapy vectors. Learn more about results achieved for the production of AAV and a paramyxovirus in the Integrity® iCELLis® bioreactor developed by ATMI LifeSciences. These results indicated titer for AAV of 5.108 vg/cm² in the small scale iCELLis (versus 3.108 vg/cm² in 5-layer stack) and 0.5-1 log titer for paramyxovirus (versus tissue culture flask). Results of transient transfection processes showed similar transfection levels in iCELLis than in the stack.